AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

Pfizer

Status and phase

Completed

Phase 2

Conditions

Psoriasis

Treatments

Drug: AN2728 ointment, 2%

Drug: Ointment Vehicle

Study type

Interventional

Funder types

Industry

Identifiers

NCT01300052

C3291017 (Other Identifier)

AN2728-PSR-204

Details and patient eligibility

About

The purpose of this study is to determine whether AN2728 topical ointment is a safe and effective treatment for mild-to-moderate plaque-type psoriasis.

Enrollment

68 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of stable mild-to-moderate plaque-type psoriasis involving 2-35% of total body surface area (BSA) excluding face, scalp, and genitals
Willingness and ability to apply study medication as directed, comply with study instructions, and commit to attending all study visits
Women of childbearing potential must agree to use contraception for the entire study period

Exclusion criteria

Any dermatological conditions that could interfere with clinical evaluations
Concurrent or recent use of certain topical or systemic medications without a sufficient washout period
Significant confounding conditions as assessed by study doctor
Participated in any other trial of an investigational drug within 30 days or participation in a research study concurrent with this study
Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)
Use of a beta-blocking medication (e.g., propranolol) if the dose has not been stabilized for at least 3 months
Pregnancy or lactation